417
Participants
Start Date
December 31, 2013
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
Placebo
Once daily, tablets, orally
Brexpiprazole
1 to 3 mg/day, once daily dose, tablets, orally
US001, The Bronx
US014, Norristown
US016, Jacksonville
US006, Gainesville
US020, North Miami
US017, Tampa
US002, Bradenton
US011, Memphis
US009, Cincinnati
US005, Dayton
US012, Indianapolis
US003, Austin
US019, Las Vegas
US004, Los Angeles
US025, Los Angeles
US015, San Diego
US008, San Diego
US024, Riverside
US010, Portland
US026, Seattle
US021, Roslindale
US007, Nashua
EE001, Tallinn
FI002, Helsinki
FI003, Helsinki
FI001, Kuopio
FI006, Oulu
FI005, Tampere
FI004, Turku
FR002, Fort de France
FR003, Laxou
FR004, Nîmes
FR005, Thuir
FR001, Tours
IT005, Andria
IT004, Catania
IT003, Lecce
IT001, Pisa
IT002, Siena
PL003, Bialystok
PL004, Gdansk
PL005, Gdansk
PL001, Leszno
PL002, Lublin
RS006, Belgrade
RS004, Niš
RS005, Novi Kneževac
ZA006, Bloemfontein
ZA002, Cape Town
ZA003, Cape Town
ZA004, Cape Town
ZA005, Cape Town
ZA008, Durban
ZA007, Port Elizabeth
ZA001, Pretoria
ZA009, Pretoria
SE001, Falun
SE002, Stockholm
SE003, Uppsala
Collaborators (1)
Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
H. Lundbeck A/S
INDUSTRY